{"pmid":32324899,"title":"Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy.","text":["Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy.","Coronavirus Disease 19 (COVID-19) represents a public health threat worldwide and Italy at the present time is considered the epicenter of this severe infection in the western world. Unfortunately, no standardized therapy does exist for COVID-19 and a number of investigational drugs for use in patients with life-threatening COVID-19 infections have been tried. One investigational treatment being explored for COVID-19 involves the use of convalescent plasma collected from recovered COVID-19 patients.","Vox Sang","Franchini, Massimo","Marano, Giuseppe","Velati, Claudio","Pati, Ilaria","Pupella, Simonetta","Liumbruno, Giancarlo Maria","32324899"],"abstract":["Coronavirus Disease 19 (COVID-19) represents a public health threat worldwide and Italy at the present time is considered the epicenter of this severe infection in the western world. Unfortunately, no standardized therapy does exist for COVID-19 and a number of investigational drugs for use in patients with life-threatening COVID-19 infections have been tried. One investigational treatment being explored for COVID-19 involves the use of convalescent plasma collected from recovered COVID-19 patients."],"journal":"Vox Sang","authors":["Franchini, Massimo","Marano, Giuseppe","Velati, Claudio","Pati, Ilaria","Pupella, Simonetta","Liumbruno, Giancarlo Maria"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324899","week":"202017|Apr 20 - Apr 26","doi":"10.1111/vox.12940","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["Italy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664895932663070720,"score":8.518259,"similar":[{"pmid":32320384,"title":"Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.","text":["Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.","BACKGROUND: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported. RESULTS: A total of eight donors were considered for enrollment; two of them were excluded because of ineligible routine check. Of the six remaining participants, five samples were tested weakly positive by the IgM ELISA. Meanwhile, high titers of IgG were observed in five samples. The patient treated with CP did not require mechanical ventilation 11 days after plasma transfusion, and was then transferred to a general ward. CONCLUSIONS: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak. METHODS: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was also utilized for the treatment of one severe COVID-19 patient.","Aging (Albany NY)","Zhang, Libo","Pang, Rongrong","Xue, Xiang","Bao, Jingjing","Ye, Sheng","Dai, Yudong","Zheng, Yishan","Fu, Qiang","Hu, Zhiliang","Yi, Yongxiang","32320384"],"abstract":["BACKGROUND: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported. RESULTS: A total of eight donors were considered for enrollment; two of them were excluded because of ineligible routine check. Of the six remaining participants, five samples were tested weakly positive by the IgM ELISA. Meanwhile, high titers of IgG were observed in five samples. The patient treated with CP did not require mechanical ventilation 11 days after plasma transfusion, and was then transferred to a general ward. CONCLUSIONS: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak. METHODS: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was also utilized for the treatment of one severe COVID-19 patient."],"journal":"Aging (Albany NY)","authors":["Zhang, Libo","Pang, Rongrong","Xue, Xiang","Bao, Jingjing","Ye, Sheng","Dai, Yudong","Zheng, Yishan","Fu, Qiang","Hu, Zhiliang","Yi, Yongxiang"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320384","week":"202017|Apr 20 - Apr 26","doi":"10.18632/aging.103102","keywords":["sars-cov-2 virus","anti-sars-cov-2 antibodies","convalescent plasma","coronavirus disease 2019 (covid-19)","plasma donation"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Nanjing","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664815087676817409,"score":206.59279},{"pmid":32296259,"pmcid":"PMC7158785","title":"Convalescent plasma: A possible treatment of COVID-19 in India.","text":["Convalescent plasma: A possible treatment of COVID-19 in India.","In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection.","Med J Armed Forces India","Teixeira da Silva, Jaime A","32296259"],"abstract":["In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection."],"journal":"Med J Armed Forces India","authors":["Teixeira da Silva, Jaime A"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296259","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.mjafi.2020.04.006","keywords":["antibodies","asia","respiratory disease","sars-cov-2 virus"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["India","USA","Italy","Spain","India","Indian","China","India"],"countries":["Spain","China","United States","Italy","India"],"countries_codes":["ESP|Spain","CHN|China","USA|United States","ITA|Italy","IND|India"],"_version_":1664641388243845120,"score":200.15396},{"pmid":32254064,"title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19.","text":["Deployment of convalescent plasma for the prevention and treatment of COVID-19.","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. .","J Clin Invest","Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar","32254064"],"abstract":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. ."],"journal":"J Clin Invest","authors":["Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32254064","week":"202015|Apr 06 - Apr 12","doi":"10.1172/JCI138745","source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640769792671744,"score":192.61285},{"pmid":32319102,"title":"Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.","text":["Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.","This document prepared and endorsed by the Working Party on Global Blood Safety of the International Society of Blood Transfusion presents elements, as of April 2020, to take into consideration in the preparation and transfusion of COVID-19 convalescent plasma as a possible treatment approach of COVID-19. The document covers the following important factors to have in mind when considering this treatment: (a) eligibility criteria of convalescent COVID-19 patients to donate whole blood or plasma, (b) pre-screening and pre-donation testing of convalescent COVID-19 donors; (c) criteria for collection of COVID-19 plasma; (d) post-donation treatment of plasma; and (e) it offers recommendations for plasma transfusion.","Vox Sang","Epstein, Jay","Burnouf, Thierry","32319102"],"abstract":["This document prepared and endorsed by the Working Party on Global Blood Safety of the International Society of Blood Transfusion presents elements, as of April 2020, to take into consideration in the preparation and transfusion of COVID-19 convalescent plasma as a possible treatment approach of COVID-19. The document covers the following important factors to have in mind when considering this treatment: (a) eligibility criteria of convalescent COVID-19 patients to donate whole blood or plasma, (b) pre-screening and pre-donation testing of convalescent COVID-19 donors; (c) criteria for collection of COVID-19 plasma; (d) post-donation treatment of plasma; and (e) it offers recommendations for plasma transfusion."],"journal":"Vox Sang","authors":["Epstein, Jay","Burnouf, Thierry"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319102","week":"202017|Apr 20 - Apr 26","doi":"10.1111/vox.12939","keywords":["covid-19","sars-cov-2","convalescent plasma","coronavirus","preparation","transfusion"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087792160771,"score":181.44553},{"pmid":32243945,"title":"Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection.","text":["Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection.","As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the number is still increasing rapidly. Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.","Chest","Zhang, Bin","Liu, Shuyi","Tan, Tan","Huang, Wenhui","Dong, Yuhao","Chen, Luyan","Chen, Qiuying","Zhang, Lu","Zhong, Qingyang","Zhang, Xiaoping","Zou, Yujian","Zhang, Shuixing","32243945"],"abstract":["As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the number is still increasing rapidly. Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy."],"journal":"Chest","authors":["Zhang, Bin","Liu, Shuyi","Tan, Tan","Huang, Wenhui","Dong, Yuhao","Chen, Luyan","Chen, Qiuying","Zhang, Lu","Zhong, Qingyang","Zhang, Xiaoping","Zou, Yujian","Zhang, Shuixing"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243945","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.chest.2020.03.039","keywords":["sars-cov-2","convalescent plasma","critical illness"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638249392406528,"score":180.07712}]}